RTS,S malaria vaccine candidate
RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants
Results from ongoing Phase III clinical trial announced
Results from a pivotal, large-scale Phase III trial, published November 9, 2012, online in the New England Journal of Medicine (NEJM), show that the RTS,S malaria vaccine candidate can help protect African infants against malaria. When compared to immunization with a control vaccine, infants (aged 6-12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria and had similar reactions to the injection. In this trial, RTS,S demonstrated an acceptable safety and tolerability profile.
- Read the press release.
- Read the NEJM article.
- Read the NEJM editorial.
- Read Dr. David Kaslow's blog post.
- Read GAVI's statement on latest trial data.
- View related resources.
- Read about the Phase III results in 5 to 17-month-olds, released in 2011.